Activity of Delafloxacin and Comparator Fluoroquinolones against Multidrug-Resistant <i<Pseudomonas aeruginosa</i< in an In Vitro Cystic Fibrosis Sputum Model
Delafloxacin (DLX) is a recently approved fluoroquinolone with broad activity against common cystic fibrosis (CF) pathogens, including multidrug-resistant <i<Pseudomonas aeruginosa</i< (MDR-Psa). Delafloxacin has been previously shown to have excellent lung and biofilm penetration and en...
Ausführliche Beschreibung
Autor*in: |
Vaughn D. Craddock [verfasserIn] Evan L. Steere [verfasserIn] Hannah Harman [verfasserIn] Nicholas S. Britt [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch |
Erschienen: |
2023 |
---|
Schlagwörter: |
---|
Übergeordnetes Werk: |
In: Antibiotics - MDPI AG, 2013, 12(2023), 6, p 1078 |
---|---|
Übergeordnetes Werk: |
volume:12 ; year:2023 ; number:6, p 1078 |
Links: |
---|
DOI / URN: |
10.3390/antibiotics12061078 |
---|
Katalog-ID: |
DOAJ094221049 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | DOAJ094221049 | ||
003 | DE-627 | ||
005 | 20240413031525.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240413s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.3390/antibiotics12061078 |2 doi | |
035 | |a (DE-627)DOAJ094221049 | ||
035 | |a (DE-599)DOAJa87061bf6fe14efc8df3fa549ab29003 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
050 | 0 | |a RM1-950 | |
100 | 0 | |a Vaughn D. Craddock |e verfasserin |4 aut | |
245 | 1 | 0 | |a Activity of Delafloxacin and Comparator Fluoroquinolones against Multidrug-Resistant <i<Pseudomonas aeruginosa</i< in an In Vitro Cystic Fibrosis Sputum Model |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Delafloxacin (DLX) is a recently approved fluoroquinolone with broad activity against common cystic fibrosis (CF) pathogens, including multidrug-resistant <i<Pseudomonas aeruginosa</i< (MDR-Psa). Delafloxacin has been previously shown to have excellent lung and biofilm penetration and enhanced activity at lower pH environments, such as those that would be observed in the CF lung. We analyzed six Psa strains isolated from CF sputum and compared DLX to ciprofloxacin (CPX) and levofloxacin (LVX). Minimum inhibitory concentrations (MICs) were determined for DLX using standard culture media (pH 7.3) and artificial sputum media (ASM), a physiologic media recapitulating the CF lung microenvironment (pH 6.9). Delafloxacin activity was further compared to CPX and LVX in an in vitro CF sputum time-kill model at physiologically relevant drug concentrations (Cmax, Cmed, Cmin). Delafloxacin exhibited 2- to 4-fold MIC reductions in ASM, which corresponded with significant improvements in bacterial killing in the CF sputum time-kill model between DLX and LVX at Cmed (<i<p</i< = 0.033) and Cmin (<i<p</i< = 0.004). Compared to CPX, DLX demonstrated significantly greater killing at Cmin (<i<p</i< = 0.024). Overall, DLX demonstrated favorable in vitro activity compared to alternative fluoroquinolones against MDR-Psa. Delafloxacin may be considered as an option against MDR-Psa pulmonary infections in CF. | ||
650 | 4 | |a delafloxacin | |
650 | 4 | |a <i<Pseudomonas aeruginosa</i< | |
650 | 4 | |a multidrug-resistance | |
650 | 4 | |a carbapenem-resistance | |
650 | 4 | |a carbapenem-resistant <i<Pseudomonas aeruginosa</i< | |
650 | 4 | |a cystic fibrosis | |
653 | 0 | |a Therapeutics. Pharmacology | |
700 | 0 | |a Evan L. Steere |e verfasserin |4 aut | |
700 | 0 | |a Hannah Harman |e verfasserin |4 aut | |
700 | 0 | |a Nicholas S. Britt |e verfasserin |4 aut | |
773 | 0 | 8 | |i In |t Antibiotics |d MDPI AG, 2013 |g 12(2023), 6, p 1078 |w (DE-627)726120596 |w (DE-600)2681345-2 |x 20796382 |7 nnns |
773 | 1 | 8 | |g volume:12 |g year:2023 |g number:6, p 1078 |
856 | 4 | 0 | |u https://doi.org/10.3390/antibiotics12061078 |z kostenfrei |
856 | 4 | 0 | |u https://doaj.org/article/a87061bf6fe14efc8df3fa549ab29003 |z kostenfrei |
856 | 4 | 0 | |u https://www.mdpi.com/2079-6382/12/6/1078 |z kostenfrei |
856 | 4 | 2 | |u https://doaj.org/toc/2079-6382 |y Journal toc |z kostenfrei |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_DOAJ | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_23 | ||
912 | |a GBV_ILN_24 | ||
912 | |a GBV_ILN_39 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_60 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_63 | ||
912 | |a GBV_ILN_65 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_95 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_110 | ||
912 | |a GBV_ILN_151 | ||
912 | |a GBV_ILN_161 | ||
912 | |a GBV_ILN_170 | ||
912 | |a GBV_ILN_206 | ||
912 | |a GBV_ILN_213 | ||
912 | |a GBV_ILN_230 | ||
912 | |a GBV_ILN_285 | ||
912 | |a GBV_ILN_293 | ||
912 | |a GBV_ILN_602 | ||
912 | |a GBV_ILN_2014 | ||
912 | |a GBV_ILN_4012 | ||
912 | |a GBV_ILN_4037 | ||
912 | |a GBV_ILN_4112 | ||
912 | |a GBV_ILN_4125 | ||
912 | |a GBV_ILN_4126 | ||
912 | |a GBV_ILN_4249 | ||
912 | |a GBV_ILN_4305 | ||
912 | |a GBV_ILN_4306 | ||
912 | |a GBV_ILN_4307 | ||
912 | |a GBV_ILN_4313 | ||
912 | |a GBV_ILN_4322 | ||
912 | |a GBV_ILN_4323 | ||
912 | |a GBV_ILN_4324 | ||
912 | |a GBV_ILN_4325 | ||
912 | |a GBV_ILN_4338 | ||
912 | |a GBV_ILN_4367 | ||
912 | |a GBV_ILN_4700 | ||
951 | |a AR | ||
952 | |d 12 |j 2023 |e 6, p 1078 |
author_variant |
v d c vdc e l s els h h hh n s b nsb |
---|---|
matchkey_str |
article:20796382:2023----::ciiyfealxcnncmaaofurqiooeaantutdurssatpedmnseuioa |
hierarchy_sort_str |
2023 |
callnumber-subject-code |
RM |
publishDate |
2023 |
allfields |
10.3390/antibiotics12061078 doi (DE-627)DOAJ094221049 (DE-599)DOAJa87061bf6fe14efc8df3fa549ab29003 DE-627 ger DE-627 rakwb eng RM1-950 Vaughn D. Craddock verfasserin aut Activity of Delafloxacin and Comparator Fluoroquinolones against Multidrug-Resistant <i<Pseudomonas aeruginosa</i< in an In Vitro Cystic Fibrosis Sputum Model 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Delafloxacin (DLX) is a recently approved fluoroquinolone with broad activity against common cystic fibrosis (CF) pathogens, including multidrug-resistant <i<Pseudomonas aeruginosa</i< (MDR-Psa). Delafloxacin has been previously shown to have excellent lung and biofilm penetration and enhanced activity at lower pH environments, such as those that would be observed in the CF lung. We analyzed six Psa strains isolated from CF sputum and compared DLX to ciprofloxacin (CPX) and levofloxacin (LVX). Minimum inhibitory concentrations (MICs) were determined for DLX using standard culture media (pH 7.3) and artificial sputum media (ASM), a physiologic media recapitulating the CF lung microenvironment (pH 6.9). Delafloxacin activity was further compared to CPX and LVX in an in vitro CF sputum time-kill model at physiologically relevant drug concentrations (Cmax, Cmed, Cmin). Delafloxacin exhibited 2- to 4-fold MIC reductions in ASM, which corresponded with significant improvements in bacterial killing in the CF sputum time-kill model between DLX and LVX at Cmed (<i<p</i< = 0.033) and Cmin (<i<p</i< = 0.004). Compared to CPX, DLX demonstrated significantly greater killing at Cmin (<i<p</i< = 0.024). Overall, DLX demonstrated favorable in vitro activity compared to alternative fluoroquinolones against MDR-Psa. Delafloxacin may be considered as an option against MDR-Psa pulmonary infections in CF. delafloxacin <i<Pseudomonas aeruginosa</i< multidrug-resistance carbapenem-resistance carbapenem-resistant <i<Pseudomonas aeruginosa</i< cystic fibrosis Therapeutics. Pharmacology Evan L. Steere verfasserin aut Hannah Harman verfasserin aut Nicholas S. Britt verfasserin aut In Antibiotics MDPI AG, 2013 12(2023), 6, p 1078 (DE-627)726120596 (DE-600)2681345-2 20796382 nnns volume:12 year:2023 number:6, p 1078 https://doi.org/10.3390/antibiotics12061078 kostenfrei https://doaj.org/article/a87061bf6fe14efc8df3fa549ab29003 kostenfrei https://www.mdpi.com/2079-6382/12/6/1078 kostenfrei https://doaj.org/toc/2079-6382 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 12 2023 6, p 1078 |
spelling |
10.3390/antibiotics12061078 doi (DE-627)DOAJ094221049 (DE-599)DOAJa87061bf6fe14efc8df3fa549ab29003 DE-627 ger DE-627 rakwb eng RM1-950 Vaughn D. Craddock verfasserin aut Activity of Delafloxacin and Comparator Fluoroquinolones against Multidrug-Resistant <i<Pseudomonas aeruginosa</i< in an In Vitro Cystic Fibrosis Sputum Model 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Delafloxacin (DLX) is a recently approved fluoroquinolone with broad activity against common cystic fibrosis (CF) pathogens, including multidrug-resistant <i<Pseudomonas aeruginosa</i< (MDR-Psa). Delafloxacin has been previously shown to have excellent lung and biofilm penetration and enhanced activity at lower pH environments, such as those that would be observed in the CF lung. We analyzed six Psa strains isolated from CF sputum and compared DLX to ciprofloxacin (CPX) and levofloxacin (LVX). Minimum inhibitory concentrations (MICs) were determined for DLX using standard culture media (pH 7.3) and artificial sputum media (ASM), a physiologic media recapitulating the CF lung microenvironment (pH 6.9). Delafloxacin activity was further compared to CPX and LVX in an in vitro CF sputum time-kill model at physiologically relevant drug concentrations (Cmax, Cmed, Cmin). Delafloxacin exhibited 2- to 4-fold MIC reductions in ASM, which corresponded with significant improvements in bacterial killing in the CF sputum time-kill model between DLX and LVX at Cmed (<i<p</i< = 0.033) and Cmin (<i<p</i< = 0.004). Compared to CPX, DLX demonstrated significantly greater killing at Cmin (<i<p</i< = 0.024). Overall, DLX demonstrated favorable in vitro activity compared to alternative fluoroquinolones against MDR-Psa. Delafloxacin may be considered as an option against MDR-Psa pulmonary infections in CF. delafloxacin <i<Pseudomonas aeruginosa</i< multidrug-resistance carbapenem-resistance carbapenem-resistant <i<Pseudomonas aeruginosa</i< cystic fibrosis Therapeutics. Pharmacology Evan L. Steere verfasserin aut Hannah Harman verfasserin aut Nicholas S. Britt verfasserin aut In Antibiotics MDPI AG, 2013 12(2023), 6, p 1078 (DE-627)726120596 (DE-600)2681345-2 20796382 nnns volume:12 year:2023 number:6, p 1078 https://doi.org/10.3390/antibiotics12061078 kostenfrei https://doaj.org/article/a87061bf6fe14efc8df3fa549ab29003 kostenfrei https://www.mdpi.com/2079-6382/12/6/1078 kostenfrei https://doaj.org/toc/2079-6382 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 12 2023 6, p 1078 |
allfields_unstemmed |
10.3390/antibiotics12061078 doi (DE-627)DOAJ094221049 (DE-599)DOAJa87061bf6fe14efc8df3fa549ab29003 DE-627 ger DE-627 rakwb eng RM1-950 Vaughn D. Craddock verfasserin aut Activity of Delafloxacin and Comparator Fluoroquinolones against Multidrug-Resistant <i<Pseudomonas aeruginosa</i< in an In Vitro Cystic Fibrosis Sputum Model 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Delafloxacin (DLX) is a recently approved fluoroquinolone with broad activity against common cystic fibrosis (CF) pathogens, including multidrug-resistant <i<Pseudomonas aeruginosa</i< (MDR-Psa). Delafloxacin has been previously shown to have excellent lung and biofilm penetration and enhanced activity at lower pH environments, such as those that would be observed in the CF lung. We analyzed six Psa strains isolated from CF sputum and compared DLX to ciprofloxacin (CPX) and levofloxacin (LVX). Minimum inhibitory concentrations (MICs) were determined for DLX using standard culture media (pH 7.3) and artificial sputum media (ASM), a physiologic media recapitulating the CF lung microenvironment (pH 6.9). Delafloxacin activity was further compared to CPX and LVX in an in vitro CF sputum time-kill model at physiologically relevant drug concentrations (Cmax, Cmed, Cmin). Delafloxacin exhibited 2- to 4-fold MIC reductions in ASM, which corresponded with significant improvements in bacterial killing in the CF sputum time-kill model between DLX and LVX at Cmed (<i<p</i< = 0.033) and Cmin (<i<p</i< = 0.004). Compared to CPX, DLX demonstrated significantly greater killing at Cmin (<i<p</i< = 0.024). Overall, DLX demonstrated favorable in vitro activity compared to alternative fluoroquinolones against MDR-Psa. Delafloxacin may be considered as an option against MDR-Psa pulmonary infections in CF. delafloxacin <i<Pseudomonas aeruginosa</i< multidrug-resistance carbapenem-resistance carbapenem-resistant <i<Pseudomonas aeruginosa</i< cystic fibrosis Therapeutics. Pharmacology Evan L. Steere verfasserin aut Hannah Harman verfasserin aut Nicholas S. Britt verfasserin aut In Antibiotics MDPI AG, 2013 12(2023), 6, p 1078 (DE-627)726120596 (DE-600)2681345-2 20796382 nnns volume:12 year:2023 number:6, p 1078 https://doi.org/10.3390/antibiotics12061078 kostenfrei https://doaj.org/article/a87061bf6fe14efc8df3fa549ab29003 kostenfrei https://www.mdpi.com/2079-6382/12/6/1078 kostenfrei https://doaj.org/toc/2079-6382 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 12 2023 6, p 1078 |
allfieldsGer |
10.3390/antibiotics12061078 doi (DE-627)DOAJ094221049 (DE-599)DOAJa87061bf6fe14efc8df3fa549ab29003 DE-627 ger DE-627 rakwb eng RM1-950 Vaughn D. Craddock verfasserin aut Activity of Delafloxacin and Comparator Fluoroquinolones against Multidrug-Resistant <i<Pseudomonas aeruginosa</i< in an In Vitro Cystic Fibrosis Sputum Model 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Delafloxacin (DLX) is a recently approved fluoroquinolone with broad activity against common cystic fibrosis (CF) pathogens, including multidrug-resistant <i<Pseudomonas aeruginosa</i< (MDR-Psa). Delafloxacin has been previously shown to have excellent lung and biofilm penetration and enhanced activity at lower pH environments, such as those that would be observed in the CF lung. We analyzed six Psa strains isolated from CF sputum and compared DLX to ciprofloxacin (CPX) and levofloxacin (LVX). Minimum inhibitory concentrations (MICs) were determined for DLX using standard culture media (pH 7.3) and artificial sputum media (ASM), a physiologic media recapitulating the CF lung microenvironment (pH 6.9). Delafloxacin activity was further compared to CPX and LVX in an in vitro CF sputum time-kill model at physiologically relevant drug concentrations (Cmax, Cmed, Cmin). Delafloxacin exhibited 2- to 4-fold MIC reductions in ASM, which corresponded with significant improvements in bacterial killing in the CF sputum time-kill model between DLX and LVX at Cmed (<i<p</i< = 0.033) and Cmin (<i<p</i< = 0.004). Compared to CPX, DLX demonstrated significantly greater killing at Cmin (<i<p</i< = 0.024). Overall, DLX demonstrated favorable in vitro activity compared to alternative fluoroquinolones against MDR-Psa. Delafloxacin may be considered as an option against MDR-Psa pulmonary infections in CF. delafloxacin <i<Pseudomonas aeruginosa</i< multidrug-resistance carbapenem-resistance carbapenem-resistant <i<Pseudomonas aeruginosa</i< cystic fibrosis Therapeutics. Pharmacology Evan L. Steere verfasserin aut Hannah Harman verfasserin aut Nicholas S. Britt verfasserin aut In Antibiotics MDPI AG, 2013 12(2023), 6, p 1078 (DE-627)726120596 (DE-600)2681345-2 20796382 nnns volume:12 year:2023 number:6, p 1078 https://doi.org/10.3390/antibiotics12061078 kostenfrei https://doaj.org/article/a87061bf6fe14efc8df3fa549ab29003 kostenfrei https://www.mdpi.com/2079-6382/12/6/1078 kostenfrei https://doaj.org/toc/2079-6382 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 12 2023 6, p 1078 |
allfieldsSound |
10.3390/antibiotics12061078 doi (DE-627)DOAJ094221049 (DE-599)DOAJa87061bf6fe14efc8df3fa549ab29003 DE-627 ger DE-627 rakwb eng RM1-950 Vaughn D. Craddock verfasserin aut Activity of Delafloxacin and Comparator Fluoroquinolones against Multidrug-Resistant <i<Pseudomonas aeruginosa</i< in an In Vitro Cystic Fibrosis Sputum Model 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Delafloxacin (DLX) is a recently approved fluoroquinolone with broad activity against common cystic fibrosis (CF) pathogens, including multidrug-resistant <i<Pseudomonas aeruginosa</i< (MDR-Psa). Delafloxacin has been previously shown to have excellent lung and biofilm penetration and enhanced activity at lower pH environments, such as those that would be observed in the CF lung. We analyzed six Psa strains isolated from CF sputum and compared DLX to ciprofloxacin (CPX) and levofloxacin (LVX). Minimum inhibitory concentrations (MICs) were determined for DLX using standard culture media (pH 7.3) and artificial sputum media (ASM), a physiologic media recapitulating the CF lung microenvironment (pH 6.9). Delafloxacin activity was further compared to CPX and LVX in an in vitro CF sputum time-kill model at physiologically relevant drug concentrations (Cmax, Cmed, Cmin). Delafloxacin exhibited 2- to 4-fold MIC reductions in ASM, which corresponded with significant improvements in bacterial killing in the CF sputum time-kill model between DLX and LVX at Cmed (<i<p</i< = 0.033) and Cmin (<i<p</i< = 0.004). Compared to CPX, DLX demonstrated significantly greater killing at Cmin (<i<p</i< = 0.024). Overall, DLX demonstrated favorable in vitro activity compared to alternative fluoroquinolones against MDR-Psa. Delafloxacin may be considered as an option against MDR-Psa pulmonary infections in CF. delafloxacin <i<Pseudomonas aeruginosa</i< multidrug-resistance carbapenem-resistance carbapenem-resistant <i<Pseudomonas aeruginosa</i< cystic fibrosis Therapeutics. Pharmacology Evan L. Steere verfasserin aut Hannah Harman verfasserin aut Nicholas S. Britt verfasserin aut In Antibiotics MDPI AG, 2013 12(2023), 6, p 1078 (DE-627)726120596 (DE-600)2681345-2 20796382 nnns volume:12 year:2023 number:6, p 1078 https://doi.org/10.3390/antibiotics12061078 kostenfrei https://doaj.org/article/a87061bf6fe14efc8df3fa549ab29003 kostenfrei https://www.mdpi.com/2079-6382/12/6/1078 kostenfrei https://doaj.org/toc/2079-6382 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 12 2023 6, p 1078 |
language |
English |
source |
In Antibiotics 12(2023), 6, p 1078 volume:12 year:2023 number:6, p 1078 |
sourceStr |
In Antibiotics 12(2023), 6, p 1078 volume:12 year:2023 number:6, p 1078 |
format_phy_str_mv |
Article |
institution |
findex.gbv.de |
topic_facet |
delafloxacin <i<Pseudomonas aeruginosa</i< multidrug-resistance carbapenem-resistance carbapenem-resistant <i<Pseudomonas aeruginosa</i< cystic fibrosis Therapeutics. Pharmacology |
isfreeaccess_bool |
true |
container_title |
Antibiotics |
authorswithroles_txt_mv |
Vaughn D. Craddock @@aut@@ Evan L. Steere @@aut@@ Hannah Harman @@aut@@ Nicholas S. Britt @@aut@@ |
publishDateDaySort_date |
2023-01-01T00:00:00Z |
hierarchy_top_id |
726120596 |
id |
DOAJ094221049 |
language_de |
englisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">DOAJ094221049</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240413031525.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240413s2023 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3390/antibiotics12061078</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ094221049</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJa87061bf6fe14efc8df3fa549ab29003</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RM1-950</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Vaughn D. Craddock</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Activity of Delafloxacin and Comparator Fluoroquinolones against Multidrug-Resistant <i<Pseudomonas aeruginosa</i< in an In Vitro Cystic Fibrosis Sputum Model</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2023</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Delafloxacin (DLX) is a recently approved fluoroquinolone with broad activity against common cystic fibrosis (CF) pathogens, including multidrug-resistant <i<Pseudomonas aeruginosa</i< (MDR-Psa). Delafloxacin has been previously shown to have excellent lung and biofilm penetration and enhanced activity at lower pH environments, such as those that would be observed in the CF lung. We analyzed six Psa strains isolated from CF sputum and compared DLX to ciprofloxacin (CPX) and levofloxacin (LVX). Minimum inhibitory concentrations (MICs) were determined for DLX using standard culture media (pH 7.3) and artificial sputum media (ASM), a physiologic media recapitulating the CF lung microenvironment (pH 6.9). Delafloxacin activity was further compared to CPX and LVX in an in vitro CF sputum time-kill model at physiologically relevant drug concentrations (Cmax, Cmed, Cmin). Delafloxacin exhibited 2- to 4-fold MIC reductions in ASM, which corresponded with significant improvements in bacterial killing in the CF sputum time-kill model between DLX and LVX at Cmed (<i<p</i< = 0.033) and Cmin (<i<p</i< = 0.004). Compared to CPX, DLX demonstrated significantly greater killing at Cmin (<i<p</i< = 0.024). Overall, DLX demonstrated favorable in vitro activity compared to alternative fluoroquinolones against MDR-Psa. Delafloxacin may be considered as an option against MDR-Psa pulmonary infections in CF.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">delafloxacin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a"><i<Pseudomonas aeruginosa</i<</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">multidrug-resistance</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">carbapenem-resistance</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">carbapenem-resistant <i<Pseudomonas aeruginosa</i<</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">cystic fibrosis</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Therapeutics. Pharmacology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Evan L. Steere</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hannah Harman</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Nicholas S. Britt</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Antibiotics</subfield><subfield code="d">MDPI AG, 2013</subfield><subfield code="g">12(2023), 6, p 1078</subfield><subfield code="w">(DE-627)726120596</subfield><subfield code="w">(DE-600)2681345-2</subfield><subfield code="x">20796382</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:12</subfield><subfield code="g">year:2023</subfield><subfield code="g">number:6, p 1078</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3390/antibiotics12061078</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/a87061bf6fe14efc8df3fa549ab29003</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.mdpi.com/2079-6382/12/6/1078</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2079-6382</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">12</subfield><subfield code="j">2023</subfield><subfield code="e">6, p 1078</subfield></datafield></record></collection>
|
callnumber-first |
R - Medicine |
author |
Vaughn D. Craddock |
spellingShingle |
Vaughn D. Craddock misc RM1-950 misc delafloxacin misc <i<Pseudomonas aeruginosa</i< misc multidrug-resistance misc carbapenem-resistance misc carbapenem-resistant <i<Pseudomonas aeruginosa</i< misc cystic fibrosis misc Therapeutics. Pharmacology Activity of Delafloxacin and Comparator Fluoroquinolones against Multidrug-Resistant <i<Pseudomonas aeruginosa</i< in an In Vitro Cystic Fibrosis Sputum Model |
authorStr |
Vaughn D. Craddock |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)726120596 |
format |
electronic Article |
delete_txt_mv |
keep |
author_role |
aut aut aut aut |
collection |
DOAJ |
remote_str |
true |
callnumber-label |
RM1-950 |
illustrated |
Not Illustrated |
issn |
20796382 |
topic_title |
RM1-950 Activity of Delafloxacin and Comparator Fluoroquinolones against Multidrug-Resistant <i<Pseudomonas aeruginosa</i< in an In Vitro Cystic Fibrosis Sputum Model delafloxacin <i<Pseudomonas aeruginosa</i< multidrug-resistance carbapenem-resistance carbapenem-resistant <i<Pseudomonas aeruginosa</i< cystic fibrosis |
topic |
misc RM1-950 misc delafloxacin misc <i<Pseudomonas aeruginosa</i< misc multidrug-resistance misc carbapenem-resistance misc carbapenem-resistant <i<Pseudomonas aeruginosa</i< misc cystic fibrosis misc Therapeutics. Pharmacology |
topic_unstemmed |
misc RM1-950 misc delafloxacin misc <i<Pseudomonas aeruginosa</i< misc multidrug-resistance misc carbapenem-resistance misc carbapenem-resistant <i<Pseudomonas aeruginosa</i< misc cystic fibrosis misc Therapeutics. Pharmacology |
topic_browse |
misc RM1-950 misc delafloxacin misc <i<Pseudomonas aeruginosa</i< misc multidrug-resistance misc carbapenem-resistance misc carbapenem-resistant <i<Pseudomonas aeruginosa</i< misc cystic fibrosis misc Therapeutics. Pharmacology |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
cr |
hierarchy_parent_title |
Antibiotics |
hierarchy_parent_id |
726120596 |
hierarchy_top_title |
Antibiotics |
isfreeaccess_txt |
true |
familylinks_str_mv |
(DE-627)726120596 (DE-600)2681345-2 |
title |
Activity of Delafloxacin and Comparator Fluoroquinolones against Multidrug-Resistant <i<Pseudomonas aeruginosa</i< in an In Vitro Cystic Fibrosis Sputum Model |
ctrlnum |
(DE-627)DOAJ094221049 (DE-599)DOAJa87061bf6fe14efc8df3fa549ab29003 |
title_full |
Activity of Delafloxacin and Comparator Fluoroquinolones against Multidrug-Resistant <i<Pseudomonas aeruginosa</i< in an In Vitro Cystic Fibrosis Sputum Model |
author_sort |
Vaughn D. Craddock |
journal |
Antibiotics |
journalStr |
Antibiotics |
callnumber-first-code |
R |
lang_code |
eng |
isOA_bool |
true |
recordtype |
marc |
publishDateSort |
2023 |
contenttype_str_mv |
txt |
author_browse |
Vaughn D. Craddock Evan L. Steere Hannah Harman Nicholas S. Britt |
container_volume |
12 |
class |
RM1-950 |
format_se |
Elektronische Aufsätze |
author-letter |
Vaughn D. Craddock |
doi_str_mv |
10.3390/antibiotics12061078 |
author2-role |
verfasserin |
title_sort |
activity of delafloxacin and comparator fluoroquinolones against multidrug-resistant <i<pseudomonas aeruginosa</i< in an in vitro cystic fibrosis sputum model |
callnumber |
RM1-950 |
title_auth |
Activity of Delafloxacin and Comparator Fluoroquinolones against Multidrug-Resistant <i<Pseudomonas aeruginosa</i< in an In Vitro Cystic Fibrosis Sputum Model |
abstract |
Delafloxacin (DLX) is a recently approved fluoroquinolone with broad activity against common cystic fibrosis (CF) pathogens, including multidrug-resistant <i<Pseudomonas aeruginosa</i< (MDR-Psa). Delafloxacin has been previously shown to have excellent lung and biofilm penetration and enhanced activity at lower pH environments, such as those that would be observed in the CF lung. We analyzed six Psa strains isolated from CF sputum and compared DLX to ciprofloxacin (CPX) and levofloxacin (LVX). Minimum inhibitory concentrations (MICs) were determined for DLX using standard culture media (pH 7.3) and artificial sputum media (ASM), a physiologic media recapitulating the CF lung microenvironment (pH 6.9). Delafloxacin activity was further compared to CPX and LVX in an in vitro CF sputum time-kill model at physiologically relevant drug concentrations (Cmax, Cmed, Cmin). Delafloxacin exhibited 2- to 4-fold MIC reductions in ASM, which corresponded with significant improvements in bacterial killing in the CF sputum time-kill model between DLX and LVX at Cmed (<i<p</i< = 0.033) and Cmin (<i<p</i< = 0.004). Compared to CPX, DLX demonstrated significantly greater killing at Cmin (<i<p</i< = 0.024). Overall, DLX demonstrated favorable in vitro activity compared to alternative fluoroquinolones against MDR-Psa. Delafloxacin may be considered as an option against MDR-Psa pulmonary infections in CF. |
abstractGer |
Delafloxacin (DLX) is a recently approved fluoroquinolone with broad activity against common cystic fibrosis (CF) pathogens, including multidrug-resistant <i<Pseudomonas aeruginosa</i< (MDR-Psa). Delafloxacin has been previously shown to have excellent lung and biofilm penetration and enhanced activity at lower pH environments, such as those that would be observed in the CF lung. We analyzed six Psa strains isolated from CF sputum and compared DLX to ciprofloxacin (CPX) and levofloxacin (LVX). Minimum inhibitory concentrations (MICs) were determined for DLX using standard culture media (pH 7.3) and artificial sputum media (ASM), a physiologic media recapitulating the CF lung microenvironment (pH 6.9). Delafloxacin activity was further compared to CPX and LVX in an in vitro CF sputum time-kill model at physiologically relevant drug concentrations (Cmax, Cmed, Cmin). Delafloxacin exhibited 2- to 4-fold MIC reductions in ASM, which corresponded with significant improvements in bacterial killing in the CF sputum time-kill model between DLX and LVX at Cmed (<i<p</i< = 0.033) and Cmin (<i<p</i< = 0.004). Compared to CPX, DLX demonstrated significantly greater killing at Cmin (<i<p</i< = 0.024). Overall, DLX demonstrated favorable in vitro activity compared to alternative fluoroquinolones against MDR-Psa. Delafloxacin may be considered as an option against MDR-Psa pulmonary infections in CF. |
abstract_unstemmed |
Delafloxacin (DLX) is a recently approved fluoroquinolone with broad activity against common cystic fibrosis (CF) pathogens, including multidrug-resistant <i<Pseudomonas aeruginosa</i< (MDR-Psa). Delafloxacin has been previously shown to have excellent lung and biofilm penetration and enhanced activity at lower pH environments, such as those that would be observed in the CF lung. We analyzed six Psa strains isolated from CF sputum and compared DLX to ciprofloxacin (CPX) and levofloxacin (LVX). Minimum inhibitory concentrations (MICs) were determined for DLX using standard culture media (pH 7.3) and artificial sputum media (ASM), a physiologic media recapitulating the CF lung microenvironment (pH 6.9). Delafloxacin activity was further compared to CPX and LVX in an in vitro CF sputum time-kill model at physiologically relevant drug concentrations (Cmax, Cmed, Cmin). Delafloxacin exhibited 2- to 4-fold MIC reductions in ASM, which corresponded with significant improvements in bacterial killing in the CF sputum time-kill model between DLX and LVX at Cmed (<i<p</i< = 0.033) and Cmin (<i<p</i< = 0.004). Compared to CPX, DLX demonstrated significantly greater killing at Cmin (<i<p</i< = 0.024). Overall, DLX demonstrated favorable in vitro activity compared to alternative fluoroquinolones against MDR-Psa. Delafloxacin may be considered as an option against MDR-Psa pulmonary infections in CF. |
collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 |
container_issue |
6, p 1078 |
title_short |
Activity of Delafloxacin and Comparator Fluoroquinolones against Multidrug-Resistant <i<Pseudomonas aeruginosa</i< in an In Vitro Cystic Fibrosis Sputum Model |
url |
https://doi.org/10.3390/antibiotics12061078 https://doaj.org/article/a87061bf6fe14efc8df3fa549ab29003 https://www.mdpi.com/2079-6382/12/6/1078 https://doaj.org/toc/2079-6382 |
remote_bool |
true |
author2 |
Evan L. Steere Hannah Harman Nicholas S. Britt |
author2Str |
Evan L. Steere Hannah Harman Nicholas S. Britt |
ppnlink |
726120596 |
callnumber-subject |
RM - Therapeutics and Pharmacology |
mediatype_str_mv |
c |
isOA_txt |
true |
hochschulschrift_bool |
false |
doi_str |
10.3390/antibiotics12061078 |
callnumber-a |
RM1-950 |
up_date |
2024-07-03T21:57:15.955Z |
_version_ |
1803596685332447233 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">DOAJ094221049</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240413031525.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240413s2023 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3390/antibiotics12061078</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ094221049</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJa87061bf6fe14efc8df3fa549ab29003</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RM1-950</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Vaughn D. Craddock</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Activity of Delafloxacin and Comparator Fluoroquinolones against Multidrug-Resistant <i<Pseudomonas aeruginosa</i< in an In Vitro Cystic Fibrosis Sputum Model</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2023</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Delafloxacin (DLX) is a recently approved fluoroquinolone with broad activity against common cystic fibrosis (CF) pathogens, including multidrug-resistant <i<Pseudomonas aeruginosa</i< (MDR-Psa). Delafloxacin has been previously shown to have excellent lung and biofilm penetration and enhanced activity at lower pH environments, such as those that would be observed in the CF lung. We analyzed six Psa strains isolated from CF sputum and compared DLX to ciprofloxacin (CPX) and levofloxacin (LVX). Minimum inhibitory concentrations (MICs) were determined for DLX using standard culture media (pH 7.3) and artificial sputum media (ASM), a physiologic media recapitulating the CF lung microenvironment (pH 6.9). Delafloxacin activity was further compared to CPX and LVX in an in vitro CF sputum time-kill model at physiologically relevant drug concentrations (Cmax, Cmed, Cmin). Delafloxacin exhibited 2- to 4-fold MIC reductions in ASM, which corresponded with significant improvements in bacterial killing in the CF sputum time-kill model between DLX and LVX at Cmed (<i<p</i< = 0.033) and Cmin (<i<p</i< = 0.004). Compared to CPX, DLX demonstrated significantly greater killing at Cmin (<i<p</i< = 0.024). Overall, DLX demonstrated favorable in vitro activity compared to alternative fluoroquinolones against MDR-Psa. Delafloxacin may be considered as an option against MDR-Psa pulmonary infections in CF.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">delafloxacin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a"><i<Pseudomonas aeruginosa</i<</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">multidrug-resistance</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">carbapenem-resistance</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">carbapenem-resistant <i<Pseudomonas aeruginosa</i<</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">cystic fibrosis</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Therapeutics. Pharmacology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Evan L. Steere</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hannah Harman</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Nicholas S. Britt</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Antibiotics</subfield><subfield code="d">MDPI AG, 2013</subfield><subfield code="g">12(2023), 6, p 1078</subfield><subfield code="w">(DE-627)726120596</subfield><subfield code="w">(DE-600)2681345-2</subfield><subfield code="x">20796382</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:12</subfield><subfield code="g">year:2023</subfield><subfield code="g">number:6, p 1078</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3390/antibiotics12061078</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/a87061bf6fe14efc8df3fa549ab29003</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.mdpi.com/2079-6382/12/6/1078</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2079-6382</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">12</subfield><subfield code="j">2023</subfield><subfield code="e">6, p 1078</subfield></datafield></record></collection>
|
score |
7.400075 |